Detalhe da pesquisa
1.
Bendamustine with rituximab, etoposide and carboplatin (T(R)EC) in relapsed or refractory aggressive lymphoma: a prospective multicentre phase 1/2 clinical trial.
Br J Haematol
; 183(4): 601-607, 2018 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-30596402
2.
Results of a phase I-II study of fenretinide and rituximab for patients with indolent B-cell lymphoma and mantle cell lymphoma.
Br J Haematol
; 176(4): 583-590, 2017 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-28055107
3.
Brentuximab vedotin administered to platinum-refractory, transplant-naïve Hodgkin lymphoma patients can increase the proportion achieving FDG PET negative status.
Hematol Oncol
; 33(4): 187-91, 2015 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-25236531
4.
A phase I study of pulse high-dose vorinostat (V) plus rituximab (R), ifosphamide, carboplatin, and etoposide (ICE) in patients with relapsed lymphoma.
Br J Haematol
; 161(2): 183-91, 2013 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-23356514